reported the design and synthesis of potent and selective tetrahydropyrazolo[1,5-a]pyrazine (THPP) derivatives as ATR inhibitors, specifically targeting cancer cells harbouring p53 mutations, which rely on ATR for survival. The gene discussed is TP53; the disease is cancer.